HK Stock Market Move | INNOVENT BIO (01801) rose more than 3% during trading hours. The new drug application for Erlotinib tablets was approved by the National Medical Products Administration (NMPA) for listing.

INNOVENT BIO (01801) rose more than 3% during trading, as of the time of writing, it is up 3.17% to HK$30.95, with a turnover of HK$1.48 billion. On the news front, INNOVENT BIO announced that its new drug application (NDA) for the third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) targeted drug, Osimertinib (Erlotinib tablets), has been approved by the China National Medical Products Administration (NMPA) for market launch. The drug is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients who have previously undergone EGFR-TKI treatment or after treatment and have been confirmed to have the EGFR T790M mutation. The company mentioned that Osimertinib (Erlotinib tablets) is its 14th commercialized product and will continue to strengthen the company's brand and product portfolio advantage in the field of precision treatment for lung cancer. It will also bring new treatment options for patients with late-stage EGFR-mutant NSCLC.